Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) had its target price upped by equities research analysts at Citigroup from $184.00 to $194.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup‘s target price suggests a potential upside of 107.86% from the stock’s current price.
Several other equities analysts have also recently weighed in on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $155.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 4th. UBS Group set a $137.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, August 27th. Weiss Ratings downgraded shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 22nd. Morgan Stanley increased their price objective on shares of Mirum Pharmaceuticals from $137.00 to $152.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Finally, Leerink Partners cut their price objective on Mirum Pharmaceuticals from $154.00 to $140.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $155.56.
Read Our Latest Stock Analysis on MIRM
Mirum Pharmaceuticals Price Performance
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative net margin of 134.75% and a negative return on equity of 97.25%. The company had revenue of $185.72 million for the quarter, compared to the consensus estimate of $178.07 million. During the same quarter in the previous year, the business earned $0.05 EPS. The company’s quarterly revenue was up 39.6% on a year-over-year basis. Sell-side analysts anticipate that Mirum Pharmaceuticals will post -1.47 earnings per share for the current year.
Insider Buying and Selling
In related news, SVP Jolanda Howe sold 40,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total value of $4,000,000.00. Following the sale, the senior vice president owned 1,274 shares in the company, valued at approximately $127,400. The trade was a 96.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the completion of the sale, the chief executive officer owned 194,440 shares in the company, valued at $19,187,339.20. This represents a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 90,658 shares of company stock valued at $8,826,200 over the last quarter. Corporate insiders own 8.32% of the company’s stock.
Hedge Funds Weigh In On Mirum Pharmaceuticals
Institutional investors have recently bought and sold shares of the business. ABS Investment Management LLC bought a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter worth about $245,847,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter valued at about $27,000. Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals in the 2nd quarter valued at about $44,000. State of Wyoming bought a new position in shares of Mirum Pharmaceuticals in the 2nd quarter valued at about $52,000. Finally, Fifth Third Bancorp bought a new position in shares of Mirum Pharmaceuticals in the 1st quarter valued at about $56,000.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.
Further Reading
- Five stocks we like better than Mirum Pharmaceuticals
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
